← Back to Search

Azole Antifungal

Opelconazole for Pulmonary Aspergillosis

Phase 2
Waitlist Available
Research Sponsored by Pulmocide Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a medication called opelconazole to prevent lung infections caused by Aspergillus fungus in people who have had a lung transplant. The study will last for several months, followed by a safety check. Opelconazole works by stopping the fungus from growing in the lungs, helping to prevent serious infections.

Eligible Conditions
  • Pulmonary Aspergillosis
  • Invasive Aspergillosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: OpelconazoleExperimental Treatment1 Intervention
14.8 mg opelconazole administered twice daily for 12 weeks
Group II: Standard of Care (SoC)Active Control1 Intervention
Mold-active SoC prophylaxis/pre-emptive therapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Opelconazole
2021
Completed Phase 2
~110

Find a Location

Who is running the clinical trial?

Pulmocide LtdLead Sponsor
9 Previous Clinical Trials
423 Total Patients Enrolled
1 Trials studying Pulmonary Aspergillosis
123 Patients Enrolled for Pulmonary Aspergillosis
Vice President Clinical DevelopmentStudy DirectorPulmocide Ltd
1 Previous Clinical Trials
100 Total Patients Enrolled

Media Library

PC945 (Azole Antifungal) Clinical Trial Eligibility Overview. Trial Name: NCT05037851 — Phase 2
Pulmonary Aspergillosis Research Study Groups: Opelconazole, Standard of Care (SoC)
Pulmonary Aspergillosis Clinical Trial 2023: PC945 Highlights & Side Effects. Trial Name: NCT05037851 — Phase 2
PC945 (Azole Antifungal) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05037851 — Phase 2
~26 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top